Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations

International Journal of Immunopharmacology

Volumn 19, Issue 4, 1997, Pages 195-203

  Banduwardene, R ^a   Mullen, A B ^a   Carter, K C ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

BALB c mouse; Immune responses; Leishmania donovani; Non ionic surfactant vesicle; Sodium stibogluconate

Indexed keywords

CHOLESTEROL; DICETYL PHOSPHATE; ETHYLENE GLYCOL DERIVATIVE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; INTERLEUKIN 4; NONIONIC SURFACTANT; STIBOGLUCONATE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIPROTOZOAL ACTIVITY; ARTICLE; BONE MARROW; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA DONOVANI; LEISHMANIASIS; LIVER; MALE; MOUSE; NONHUMAN; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; FEMALE; INTERFERON TYPE II; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; ORGAN SIZE; SPLEEN; SURFACE-ACTIVE AGENTS;

EID: 0030736090     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(97)00009-X     Document Type: Article

References (35)

1. Aebischer, T. (1994) Recurrent cutaneous leishmaniasis: a role for persistent parasites? Parasitol. Today, 10, 25-28.
2. Alving, C. R. (1986) Liposomes as drug carriers for leishmaniasis and malaria. Parasitol. Today, 2, 101.
3. Baillie, A. J., Dolan, T. F., Alexander, J. & Carter, K. C. (1989) Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection. Int. J. Pharmaceut., 57, 23-28.
4. Black, C. D. V., Watson, G. J. & Ward, R. J. (1977) The use of pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 30, 550.
5. Blackwell, J. M., Roberts, M. B. & Alexander, J. (1985) Response of BALB/c mice to leishmanial infection. Curr. Topics Microbiol. Immun., 122, 97-106.
6. Bradley, D. J. (1974) Genetic control of natural resistance to Leishmania donovani. Nature, 250, 353-354.
7. Bradley, D. J. & Kirkley, J. (1977) Regulation of Leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice. Clin. Exp. Immunol., 30, 119-129.
8. Brewer, J. M., Connacher, M., Satoskar, A., Bluethmann & Alexander, J. (1996) In interleukin-4-deficient mice, alum not only generates T helper responses equivalent to Freund's complete adjuvant, but continues to induce T helper cytokine production. Eur. J. Immun., 26, 2062-2066.
9. Carter, K. C., Baillie, A. J., Alexander, J. & Dolan, T. F. (1988) The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ dependent. J. Pharm. Pharmac., 40, 370.
10. Carter, K. C., Dolan, T. F., Baillie, A. J. & Alexander, J. (1989b). The limitations of carrier mediated sodium stibogluconate therapy in a BALB/c mouse model of visceral leishmanasis. In Liposomes in the Therapy of Infectious Diseases and Cancer, pp. 215-226. Alan R. Liss Inc., New York.
11. Carter, K. C., O'Grady, J., Dolan, T. F., Bailie, A. J., Alexander, J. & Keys, J. (1989) A direct comparison of sodium stibogluconate treatment in two animal models of human visceral leishmanasis. Int. J. Pharmaceut., 53, 129-137.
12. Chance, M. L. (1995) New developments in the chemotherapy of leishmaniasis. Ann. trop. Med. Parasitol., 79, 27-43.
13. Chulay, J. D., Fleckenstein, L. & Smith, D. H. (1988) Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg., 82, 69-72.
14. Collins, M., Baillie, A. J. & Carter, K. C. (1992) Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection: II changes in tissue drug distribution. Int. J. Pharmaceut., 83, 251-256.
15. Davidson, R. N. & Konecny, P. (1995) Immunology and treatment of leishmaniases. Curr. Opinion infect. Dis., 8, 336-341.
16. Elassad, A. M. S., Younis, S. A., Siddig, M., Grayson, J., Petersen, E. & Ghalib, H. W. (1994) The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients. Clin. exp. Immun., 95, 294-299.
17. Finkelmann, F. D. & Holmes, J. (1990) Lymphokine control of in vivo immunoglobulin isotype selection. A. Rev. Immun., 8, 303-333.
18. Ghalib, H. W., Pluvezam, M. R., Skelky, Y. A. W., Siddig, M., Hashim, F. A., El-Hassan, A. M., Russo, D. M. & Reed S. G. (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. clin. Invest., 92, 324-329.
19. Grevelink, S. A. & Lerner, E. A. (1996) Leishmaniasis. J. Am. Acad. Sci., 34, 257-272.
20. James, S. L. (1995) Role of nitric oxide in parasitic infections. Microbiol. Rev., 59, 533-547.
21. Kemp, M., Theander, T. G. & Kharazami, A. (1996) The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immun. Today, 17, 13-16.
22. Moll, H., Flohe, S. & Rollinghoff, M. (1995) Dendrietic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response. Eur. J. Immun., 25, 693-699.
23. Mossman, T. R. & Coffmann, R. L. (1989) TH1 and Th2 cells: different patterns of lymphokine secretion leads to different functional properties. A. Rev. Immun., 7, 145-173.
24. Murray, H. W. (1994) Cytokines in the treatment of leishmaniases. Clin. infect. Dis., 1, 127-140.
25. Murray, H. W., Berman, J. D. & Wright, S. D. (1988) Immunochemotherapy for intracellular Leishmania donovani infection: interferon γ plus pentavalent antimony. J. infect. Dis., 157, 973-978.
26. Pearson, R. D., de Queiroz Sousa, A. (1996) Clinical spectrum of leishmaniasis. Clin. infect. Dis., 22, 1-13.
27. Rees, P. H., Kating, M. I., Kager, P. A. & Hockmeyer, W. T. (1980) Renal clearnace of pentavalent antimony-sodium stibogluaonet. Lancet, ii, 226-229.
28. Rossell, R. A., de Jesu de Duran, R., Rosell, O. & Rodriguez, A. M. (1992) Is leishmaniasis ever cured?. Trans. R. Soc. Trop. Med. Hyg., 86, 252-253.
29. Sacks, D. L., Louis, J. & Wirth, D. F. (1993) Leishmaniasis. In Immunology and Molcular Biology of Parasitic Infections (ed. Warren, K. S.), pp. 237-268. Blackwell Science Ltd., Oxford, U.K.
30. Saha, B., Das, G., Vohra, H., Ganguly, N. K., Mishra, G. C. (1995) macrophage-T cell intercation in experimental visceral leishmaniasis: failure to express co-stimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity. Eur. J. Immun., 25, 2492-2498.
31. Sundar, S., Rosenkaimer, F. & Murray, H. W. (1994) Successful treatment of refactory visceral leishmaniais in India using antimony plus interferon γ. J. infect. Dis., 170, 659-662.
32. Vanlerberghe, G. & Morancais, J. L. (1996) Niosomes in perspective. STP Pharma Sci., 6, 5-11.
33. Ward, R. J., Black, C. D. V. & Watson, G. J. (1979) Determination of antimony in biological materials be visceral leishamaniasis. Clinica chim. Acta, 99, 143-152.
34. Williams, D. M., Carter, K. C. & Baillie, A. J. (1995) Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate. J. Drug. Target., 3, 1-7.
35. WHO (1995). Leishmaniasis. Twelfth Programme report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. WHO, Geneva, pp. 135-1.